Protein Design Labs (PDLI)
Oppenheimer's Geller began coverage with a "buy" and a one-year target of $35. He said the Mountain View, Calif., company has one of the largest, strongest pipelines in biotech, with two technology platforms for generating humanized and human monoclonal antibodies that have created 13 products at various stages of development.